Sigachi Laboratories Limited Unlisted Share
₹52▲0.00%(0.00)
About the company
Sigachi Laboratories Limited is an Indian pharmaceutical company engaged in the manufacturing and supply of bulk drugs, drug intermediates, and pharmaceutical products. The company operates from its registered office and manufacturing facility in Sangareddy District, Telangana, and has established its presence in the pharmaceutical sector by focusing on quality manufacturing, regulatory compliance, and operational efficiency.
The company's core business revolves around producing pharmaceutical ingredients that serve as essential building blocks in the manufacturing of medicines. In addition to its pharmaceutical operations, Sigachi Laboratories also generates income from interest on loans, inter-corporate deposits (ICDs), and fixed deposits, contributing to its overall financial performance.
Fundamentals
Valuation
| Metric | Value |
|---|---|
| 52 week high | ₹52 |
| 52 week low | ₹52 |
| P/B ratio | 0.89 |
| Debt to equity | 0 |
| ROE (%) | 3.03% |
| Book value | ₹58.39 |
| Face value | ₹10 |
52 week high
52 week low
P/B ratio
ROE (%)
| Metric | Value |
|---|---|
| 52 week high | ₹52 |
| 52 week low | ₹52 |
| P/B ratio | 0.89 |
| ROE (%) | 3.03% |
Registry
| Metric | Value |
|---|---|
| PAN number | AACCS8220M |
| ISIN number | INE368H01018 |
Figures in lk ·
Financials
| P&L Statement | 2025Latest | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 312 | 374 | 195 | 260 | 348 | 66 | 169.54 | 176.24 |
| EBITDA | 109 | 242 | 142 | 211 | 293 | 25 | 113.89 | 113.64 |
| OPM | 34.94 | 64.71 | 72.82 | 81.15 | 84.2 | 37.88 | 67.18 | 64.48 |
| PBT | 152 | 281 | 173 | 238 | 314 | 116 | 127.39 | 133.89 |
| PAT | 119 | 197 | 131 | 200 | 276 | 70 | 104.51 | 111.1 |
| EPS | 1.63 | 2.69 | 1.79 | 2.74 | 3.78 | 0.96 | 1.43 | 1.52 |
Shareholding Pattern
Promoters
Resident Individual
NRI
Others
| Holder | Percentage |
|---|---|
| Promoters | 36.86% |
| Resident Individual | 40.59% |
| NRI | 20.48% |
| Others | 2.07% |
Leadership
| Name | Role | Experience | |
|---|---|---|---|
| Sri. T. Adinarayana | Chairman | 30+ yrs experience | — |
| Sri. T.R. Sekhar | Executive Director | 25+ yrs experience | — |
| Mr. B. Kumar | CFO | 25+ yrs experience | — |
Frequently asked questions
Common questions on Sigachi Laboratories Limited Unlisted Share—tap a row to read the answer.
Q.1What is Sigachi Laboratories Limited?
Sigachi Laboratories Limited is an Indian pharmaceutical company engaged in the manufacturing of bulk drugs, drug intermediates, and other pharmaceutical products. The company also earns income from interest-bearing investments such as inter-corporate deposits (ICDs), loans, and fixed deposits. With its focus on quality manufacturing and operational efficiency, the company serves the pharmaceutical industry's growing demand for active ingredients and intermediates.
Q.2Can I invest in Sigachi Laboratories Limited unlisted shares?
Yes, if Sigachi Laboratories Limited unlisted shares are available in the private market, eligible investors can purchase them through private share transactions. Since these shares are not traded on major stock exchanges, their availability depends on existing shareholders willing to sell and prevailing market demand.
Q.3How can I buy Sigachi Laboratories Limited unlisted shares?
You can buy Sigachi Laboratories Limited unlisted shares through authorized intermediaries that facilitate private share transactions. Once the price, quantity, and documentation are finalized, the shares are transferred electronically to your Demat account after successful payment and verification.
Q.4How is the price of Sigachi Laboratories Limited unlisted shares determined?
The price of Sigachi Laboratories Limited unlisted shares is generally influenced by several factors, including the company's financial performance, profitability, business outlook, pharmaceutical industry trends, recent private market transactions, investor demand, and overall market sentiment. Since the shares are privately traded, prices are determined through negotiations rather than exchange-based trading.
Q.5Is it legal to buy Sigachi Laboratories Limited unlisted shares in India?
Yes. Buying and selling unlisted shares is legal in India when the transaction complies with applicable laws and regulatory requirements. Investors should ensure that the transfer is completed with proper documentation and that the shares are credited to their Demat account.
Q.6Do I need a Demat account to hold Sigachi Laboratories Limited unlisted shares?
Yes. An active Demat account is generally required to receive and hold Sigachi Laboratories Limited unlisted shares in electronic form. It provides secure ownership records and makes future transfers or sales more convenient.
Unlisted Trending shares
High-demand unlisted opportunities currently available for trade.
MARKET INSIGHTS & UPDATES
Read the latest updates, investment ideas, and market insights designed to help investors better understand unlisted and pre-IPO opportunities.

Muthoot FinCorp Unlisted Shares: Q1FY27 Profit Surges to ₹705 Cr | Fundamentals & IPO
Muthoot FinCorp's Q1FY27 profit surged to ₹705.48 crore as the company moves toward a proposed ₹3,000-crore IPO. Here's a look at its financial performance, valuation metrics, asset quality and key fundamentals.

From Debt to Debt-Free: How API Holdings Used Thyrocare to Reshape Its Balance Sheet
API Holdings has repaid ₹1,050 crore of debt by monetising a 9.90% stake in Thyrocare while retaining 51.02% control. Here's how the move reshapes its balance sheet and what it means going forward.

Pre IPO Shares in India: Price, How to Buy & Complete Guide
Learn what Pre IPO Shares are, how their prices are determined, how to buy them in India, and what investors should check before investing in unlisted companies.

Unlisted Shares Price List India | Buy Pre IPO Shares Online
The Unlisted Shares Price List India helps investors track the latest prices of privately traded companies before they are listed on stock exchanges. This guide explains what Unlisted Shares and Pre IPO Shares are, how their prices are determined, and the factors that influence their valuation. It also covers the benefits, risks, taxation, and step-by-step process of buying unlisted shares in India. Additionally, the article highlights popular companies such as NSE India, OYO, API Holding (Pharm Easy), MSEI, Gamma Rotors, Zepto, Orbis Financial, and Motilal Oswal Home Finance, providing readers with a comprehensive understanding of India's growing pre-IPO market. Whether you're a new or experienced investor, this guide offers practical insights to help you make informed investment decisions.

NSE IPO Moves Closer: SEBI Approval Expected by Mid-August, Listing May Happen in September
The National Stock Exchange (NSE) IPO is moving closer to listing, with SEBI's approval for the IPO draft expected by mid-August 2026, according to NDTV Profit sources. If the remaining regulatory process is completed on time, NSE could be listed in September 2026, subject to final approvals and market conditions. A key development is the expected final settlement order in the NSE co-location case, with the settlement amount likely to exceed ₹1,400 crore. Meanwhile, NSE has reportedly begun domestic and international investor roadshows as part of its IPO preparations. While these updates indicate strong momentum toward the IPO, the final timeline remains subject to SEBI approval and official announcements.

NCDEX Launches 'Nidhi' Mutual Fund Platform: A New Chapter in India's Financial Inclusion Journey
NCDEX has launched the 'Nidhi' Mutual Fund Platform, marking a significant step toward expanding financial inclusion across rural and semi-urban India. The platform aims to simplify mutual fund investments by leveraging NCDEX's extensive FPO and agri-network, making investment opportunities more accessible to underserved communities. With six leading Asset Management Companies (AMCs) onboard at launch, the initiative seeks to encourage wider participation in India's mutual fund ecosystem and promote long-term wealth creation. Discover the key features, benefits, and potential impact of the NCDEX Nidhi Mutual Fund Platform, and learn how this strategic move strengthens NCDEX's presence beyond commodity markets while supporting the growth of India's financial ecosystem.
